SERINC2 (serine incorporator 2) is a transmembrane protein that functions as a non-ATP-dependent lipid transporter and scramblase, facilitating bidirectional flipping of phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine across membranes 1. Beyond its established lipid transport role, SERINC2 demonstrates significant involvement in cellular metabolism and disease pathogenesis. In cancer contexts, SERINC2 promotes tumor progression through multiple mechanisms: it enhances serine metabolism and serine-associated lipid synthesis, creates immunosuppressive microenvironments by competing with CD8+ T cells for serine and inducing T cell exhaustion, and activates the Myc pathway to drive cervical cancer cell proliferation and metastasis 23. SERINC2 also localizes to lysosomes where it regulates amino acid/mTORC1 signaling, with its deficiency leading to pathological cardiac hypertrophy through enhanced mTORC1 activity and protein synthesis 4. In neuropsychiatric disorders, SERINC2 deficits in microglia impair phospholipid synthesis and synaptic pruning, contributing to bipolar disorder pathogenesis 5. Genome-wide association studies have identified SERINC2 as a significant risk locus for alcohol dependence in European populations 67. Pan-cancer analyses reveal SERINC2 overexpression correlates with poor prognosis and altered immune infiltration across multiple tumor types 8.